Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 3/20 | 0.54 |
| ▸ | OPRD1 | P41143 | 7/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8824371 | 0.89 | OPRD1 (0.54) | APPOPRD1OPRM1OPRK1MAPT | |
| SCHEMBL13689912 | 0.86 | MEN1 (0.56) | OPRD1OPRK1L3MBTL1 | |
| SCHEMBL21581202 | 0.82 | OPRD1 (0.63) | APPOPRD1OPRM1OPRK1MAPT | |
| SCHEMBL442118 | 0.82 | TSHR (0.54) | OPRD1OPRK1TSHRKDM4E | |
| SCHEMBL12162991 | 0.81 | USP2 (0.53) | OPRD1OPRM1OPRK1TSHRGAA | |
| SCHEMBL3531048 | 0.81 | KMT2A (0.45) | OPRM1TSHRALDH1A1 | |
| SCHEMBL22874143 | 0.80 | APP (0.56) | APPOPRD1OPRM1OPRK1MAPT | |
| SCHEMBL14348178 | 0.79 | LMNA (0.41) | APPOPRD1OPRM1OPRK1MAPT | |
| SCHEMBL20004190 | 0.79 | HSD11B1 (0.60) | APPOPRD1OPRM1OPRK1MAPT | |
| SCHEMBL11624342 | 0.78 | APP (0.52) | APPOPRD1OPRM1OPRK1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180086757-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180086757-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | JAK1, JAK2, JAK3 | APP 3260/4885OPRD1 709/4885OPRM1 697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.